Please provide your email address to receive an email when new articles are posted on . Among patients with peripheral artery disease, the use of vorapaxar appears to reduce peripheral ...

Peripheral Artery Revascularization Market has been evolving and changing over the course of past few decades and the market scope has changed a lot over the course of time and to better understand ...

Please provide your email address to receive an email when new articles are posted on . IVUS may improve care of patients undergoing peripheral revascularization. More data are needed to document ...

Both the incidence and degree of bleeding events after peripheral revascularization match what’s seen for coronary revascularization and for lower-extremity amputation, new findings from the EUCLID ...

In the Losartan Intervention For End point reduction in hypertension (LIFE) study losartan- compared to atenolol-based antihypertensive treatment showed a tendency towards reducing peripheral ...

October 9, 2009 (Vienna, Austria) — A reduction in major amputations associated with diabetic foot followed the increased rates of peripheral revascularization that occurred after implementation of ...

People who took rivaroxaban (Xarelto) after lower-extremity revascularization for peripheral artery disease (PAD) enjoyed fewer subsequent major adverse limb and cardiovascular events, according to ...

The mechanism remains unclear, but GLP-1 users had less MACE, CV death, and all-cause death driven by fewer amputations.

Compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors were associated with lower risks of cardiac death and composite renal outcomes without ...

BOSTON - Peripheral arterial disease (PAD), a vascular condition that prevents blood flow to the extremities, currently affects 8.5 million people in the United States. A study of nearly 62,000 ...

Lower extremity artery disease (LEAD) is a leading cause of morbidity and mortality worldwide, affecting hundreds of millions of people. On top of that, LEAD also represents a prominent marker of ...

"Our findings highlight the clinical importance of focusing on total disease burden, rather than first events, and the need for long-term preventive strategies in high-risk patients."—Michael Szarek, ...